Cognitive & Neurological
PE22-28
Antidepressant peptide derived from the TREK-1 channel. It demonstrates rapid antidepressant effects (within hours) in preclinical models, with the potential to overcome the limitations of current antidepressants.
Also known as: Spadin analogue
Specifications
| Research area | Cognitive & Neurological | ||
|---|---|---|---|
| Half-life | ~1–2 hours | ||
| Molecular weight | 830.0 Da | ||
| Amino acid residues | 7 | ||
Research areas
AntidepressantSerotonergicCognitionAnxiety
- Mechanism of action
- Blocks the TREK-1 potassium channel, which increases the excitability of serotonergic neurons in the raphe. The effect is similar to SSRIs but with a much faster onset of action.
- Reported research ranges
- In preclinical research. Human dosages not established.
- Reported adverse effects
- Limited data. Experimental.
- Storage and handling
- Refrigerate at 2–8 °C.
This material is published for scientific and educational reference. It is not medical advice, not a treatment recommendation, and not an offer to sell. Compounds discussed are for research and laboratory use only.
← All compounds